Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong Earnings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) saw unusually-strong trading volume on Thursday following a stronger than expected earnings report. Approximately 1,049,409 shares changed hands during trading, a decline of 15% from the previous session’s volume of 1,241,134 shares.The stock last traded at $7.61 and had previously closed at $7.95.

The biotechnology company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.05 by $0.04. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of large investors have recently bought and sold shares of AUPH. SBI Securities Co. Ltd. bought a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth $27,000. Tower Research Capital LLC TRC boosted its position in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $31,000. Finally, Natixis bought a new position in Aurinia Pharmaceuticals in the fourth quarter worth about $49,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

The firm has a market capitalization of $1.07 billion, a P/E ratio of -49.96 and a beta of 1.22. The stock’s fifty day simple moving average is $8.22 and its 200 day simple moving average is $7.77. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.